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Proliferating cell nuclear antigen (PCNA) is a DNA
clamp essential for DNA replication. During DNA
synthesis, PCNA is continuously loaded onto and un-
loaded from DNA. PCNA recruits various proteins to
nascent DNA to facilitate chromosome duplication.
Therefore, timely PCNA unloading is crucial for
high-fidelity DNA replication. The ATAD5-RFC-like
complex (ATAD5-RLC) unloads PCNA from repli-
cated DNA. It is unclear how ATAD5-RLC activity is
regulated to prevent premature PCNA unloading.
Here, we find that BRD4, an acetyl-histone-binding
chromatin reader, inhibits the PCNA-unloading activ-
ity of ATAD5-RLC. The BRD4 ET domain interacts
with a region upstream of the ATAD5 PCNA-unload-
ing domain. BRD4-ATAD5 binds to acetyl-histones in
nascent chromatin. BRD4 release from chromatin
correlates with PCNA unloading. Disruption of the
interaction betweenBRD4 and acetyl-histones or be-
tween BRD4 and ATAD5 reduces the PCNA amount
on chromatin. In contrast, the overexpression of
BRD4 increases the amount of chromatin-bound
PCNA. Thus, acetyl-histone-bound BRD4 fine-tunes
PCNA unloading from nascent DNA.INTRODUCTION
Eukaryotic DNA replication is tightly regulated for the accurate
duplication of the genome (Kang et al., 2018). During DNA repli-
cation, many kinds of replication proteins sequentially associate
with replication forks. Timely assembly and disassembly of repli-
cation machinery on replicating DNA are crucial for efficient and
accurate DNA replication.
Proliferating cell nuclear antigen (PCNA) is a DNA clamp
that tethers DNA polymerases to replicating DNA to enhance
polymerase processivity. PCNA functions as a molecular plat-
form for many proteins that participate in DNA replication and
repair (Moldovan et al., 2007). PCNA also plays important
roles in nascent chromatin assembly. PCNA interacts with
CAF-1, a histone chaperone, and participates in nucleosome4632 Cell Reports 29, 4632–4645, December 24, 2019 ª 2019 The A
This is an open access article under the CC BY-NC-ND license (http://deposition on nascent DNA (Shibahara and Stillman, 1999;
Zhang et al., 2000). An interplay between PCNA and the
BAZ1B-SMARCA5 complex, a chromatin remodeler, was
also reported (Poot et al., 2004). The BAZ1B-SMARCA5 com-
plex and PCNA work together to appropriately assemble
nascent chromatin.
PCNA must be removed from DNA after DNA synthesis and
nascent chromatin assembly. The prolonged presence of
PCNA on replicated chromatin results in the inappropriate
recruitment of replication proteins that causes genome instability
(Lee et al., 2013). PCNA is a homotrimer that forms a closed ring.
The PCNA ring needs to be opened and closed to encircle DNA.
DNA loading and unloading of PCNA are mediated by three
clamp-loader complexes: replication factor C (RFC) and two
RFC-like complexes (RLCs). RFC and CTF18-RLC load PCNA
onto primer-template junctions, and ATAD5-RLC unloads
PCNA (Kang et al., 2018, 2019). PCNA unloading by ATAD5-
RLC is important for the maintenance of genomic integrity (Lee
et al., 2013).
DNA replication is tightly coupled with chromatin disassembly
and reassembly (Kurat et al., 2017; Petryk et al., 2018; Reveron-
Gomez et al., 2018; Yu et al., 2018). Parental nucleosomes are
dismantled ahead of replicative helicase. Behind the replication
fork, nucleosomes are reassembled on DNA immediately after
DNA synthesis. During nascent chromatin assembly, disas-
sembled parental histones are transferred to newly replicated
DNA. Along with parental histones, newly synthesized histones
are deposited on nascent DNA. In a human cell, new histones
are acetylated at K5 and K12 of histone H4 (Loyola et al., 2006;
Sobel et al., 1995).
Histone modifications, such as acetylation and methylation,
are recognized by chromatin readers. Each chromatin reader
binds to distinctively modified histones and recruits effector
molecules to the chromatin. BET family proteins, such as
BRD2, BRD3, and BRD4, are chromatin readers that specif-
ically bind to acetylated histones. Two bromodomains
(BDs) in BET proteins recognize acetylated histones. BET
proteins have an additional conserved domain called the ex-
tra-terminal (ET) domain. Through the ET domain, BET pro-
teins interact with a wide range of effector molecules that
regulate transcription, DNA replication, and repair (Donati
et al., 2018).
Because BRD4 is a key transcription regulator for many
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investigated thoroughly. BRD4 recruits different kinds of tran-
scriptional regulators to acetylated chromatin and organizes su-
per-enhancers (Sabari et al., 2018). BRD4 interacts with histone
modifiers such as JMJD6 and NSD3 and chromatin remodelers
such as CHD4 to facilitate transcription initiation (Jones and Lin,
2017; Konuma et al., 2017; Liu et al., 2013; Shen et al., 2015;
Zhang et al., 2016). BRD4 also binds to the positive transcription
elongation factor b (P-TEFb) and promotes transcription elonga-
tion (Jang et al., 2005; Yang et al., 2005). Growing evidence sug-
gests that BRD4 performs important functions in DNA replication
and repair. BRD4 recruits TICRR to euchromatin for timely repli-
cation initiation (Sansam et al., 2018). TICRR is a helicase-acti-
vating protein that is required for replication origin firing. BRD4
binds to RFC, and their interaction is reported to be important
for proper S phase progression (Maruyama et al., 2002). During
double-strand break repair, BRD4 interacts with 53BP1 and sta-
bilizes it at the break sites (Li et al., 2018). BRD4 is regarded as a
major therapeutic target in many diseases because of its pivotal
roles in cell proliferation (Korb et al., 2017; Sun et al., 2018; White
et al., 2019).
Given that PCNA is important for nascent chromatin assembly,
PCNA unloading from nascent DNA should be coordinated with
nucleosome deposition. In yeast, Elg1, a homolog of ATAD5, co-
operates with histone chaperone Rtt106 to facilitate nascent
chromatin organization (Gali et al., 2018). Nevertheless, re-
searchers have not fully elucidated how the activity of ATAD5-
RLC is regulated to coordinate PCNA unloading with nascent
chromatin assembly.
Here, we found that BET proteins fine-tune the PCNA-
unloading activity of ATAD5-RLC. The ET domain of BRD4
interacted with an ATAD5 fragment (positions 596–692, hereafter
called ATAD5 (596–692)) that is located immediately upstream of
the PCNA-unloading domain. Acetyl-histone-bound BRD4 in-
hibited the PCNA-unloading activity of ATAD5-RLC. Our results
suggest that PCNA unloading from replicated DNA is regulated
by the acetylation status of nascent chromatin.Figure 1. BET Proteins Interact with the N-Terminal Domain of ATAD5
(A) The domain diagram of human ATAD5. The N-terminal domain of ATAD5 intera
C-terminal AAA+ ATPase domain of ATAD5 and RFC2–5 form an RFC-like comp
(B) ATAD5 (1–692) binds to nascent DNA. iPOND analysis was performed after the
harvested at indicated time points after the thymidine chase. Endogenous ATAD5
DNA was analyzed by immunoblotting.
(C) BET proteins bind to ATAD5 (1–692). Affinity purification mass spectrometry
noprecipitated proteins were analyzed by SDS-PAGE with Coomassie staining.
cipitate of FLAG-ATAD5 (1–692). MS results are summarized and highly enriched
(D) ATAD5 interacts with BRD2, BRD3, and BRD4. Transiently expressed full-leng
BRD2, BRD3, and BRD4 were analyzed by immunoblotting. BRD4 was more enric
each blot indicate the relative amount of BRD2, BRD3, or BRD4.
(E) Endogenous ATAD5 interacts with BRD4A. Endogenous ATAD5 was immun
BRD4A was analyzed by immunoblotting.
(F) ATAD5 interacts with all three isoforms of BRD4. Top panel: a domain diagram o
the lysates of cells transiently coexpressing FLAG-ATAD5 and V5-tagged BRD4
(G) The BRD4 ET domain is crucial for ATAD5 binding. Top panel: a diagram of B
deletion. Bottom panel: the interactions between FLAG-ATAD5 and V5-tagged BR
BRD4 mutant failed to interact with ATAD5.
(H) The BRD4 ET domain is an ATAD5-interacting motif. Top panel: a diagram of
deletion. The nuclear localization signal (NLS) of BRD4, BRD4 (286–297), was fu
(597–674), was sufficient for ATAD5 binding.
See also Figure S1.
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ATAD5 Is Enriched on Nascent DNA
Human ATAD5 is a multi-domain protein (Figure 1A) (Kang et al.,
2019). ATAD5 (693–1,844) interacts with RFC2-5 to form an RLC
that has a PCNA-unloading activity. The N-terminal domain of
ATAD5 interacts with UAF1 and participates in the deubiquitina-
tion of ubiquitinated PCNA (Lee et al., 2010). As expected from
its replication-related functions, iPOND (isolation of proteins on
nascent DNA) analysis showed that ATAD5 was enriched
on nascent DNA (Figure S1A) (Lopez-Contreras et al., 2013).
ATAD5 dissociated from nascent DNA after a thymidine chase
procedure, when PCNA disappeared from the nascent DNA.
Of note, ATAD5 (1–692) was more strongly enriched on nascent
DNA as compared to ATAD5 (693–1,844) (Figures 1B and S1B).
The release time of ATAD5 (1–692) from nascent DNAwas similar
to that of PCNA. Because ATAD5-RLC functions as a PCNA un-
loader, the coexistence of PCNA and ATAD5 (1–692) on nascent
DNA implies that the unloading activity of ATAD5-RLC may be
regulated through its N-terminal domain.
The ET Domain of BET Proteins Interacts with ATAD5
In addition to the UAF1-binding motif, ATAD5 (1–692) contains
several well-conserved motifs whose functions have not been
characterized (FigureS1C). Thesemotifsmayactasdocking inter-
faces for a regulatory factor that controls ATAD5-RLC activity. To
uncover the functional regulators of ATAD5-RLC, we affinity puri-
fied ATAD5 (1–692) after transient expression. Mass spectro-
metric analysis was performed for the identification of the coiso-
lated proteins (Figure 1C). Enrichment of UAF1 with ATAD5
(1–692) validated our experimental setup (Lee et al., 2010). More-
over, BET proteins—BRD2, BRD3, and BRD4—were found to be
coisolatedwithATAD5 (1–692). BETproteins are known to interact
withacetyl-histonessuchasH4K5AcandH4K12Ac,whichare en-
riched in nascent chromatin (Figures 1B and S1A). Our iPOND
analysis showed that BRD4 was recruited to the nascentcts with UAF1 and participates in deubiquitination of ubiquitinated PCNA. The
lex (RLC) that possesses PCNA-unloading activity.
EdU pulse-chase procedure. Cells transiently expressing ATAD5 (1–692) were
was depleted by siRNA. The association of the indicated proteins with nascent
(AP-MS) was performed with FLAG-ATAD5 (1–692). Left panel: FLAG-immu-
Right panel: BRD2, BRD3, and BRD4 were enriched in the FLAG immunopre-
proteins are shown in the table.
th FLAG-ATAD5 was immunoprecipitated, and coprecipitations of endogenous
hed in the immunoprecipitate as compared to BRD2 or BRD3. Numbers below
oprecipitated using an anti-ATAD5 antibody, and coisolation of endogenous
f BRD4 isoforms. Bottom panel: FLAG-immunoprecipitation was performed on
isoforms.
RD4 mutants examined for ATAD5 interaction. Numbers indicate positions of
D4mutants were analyzed by FLAG-immunoprecipitation. The ET domain-null
BRD4 mutants examined for ATAD5 interaction. Numbers indicate positions of
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chromatin where acetyl-histones were enriched (Figure S1A).
BRD4 dissociated from nascent DNA after the thymidine chase
procedure. Given that reduction in the amount of acetyl-histones
coincides with the dissociation of BRD4 and PCNA from nascent
DNA, BET proteins may regulate PCNA unloading from nascent
DNA. To understand how BET proteins control the activity of
ATAD5-RLC, we first investigated the interaction between them
(Figure 1D). In agreementwith affinity purificationmass spectrom-
etry (AP-MS) results (Figure 1C), endogenous BRD2, BRD3, and
BRD4 were coprecipitated with FLAG-ATAD5. BRD4 was more
enrichedwithATAD5as compared toBRD2andBRD3. This result
suggests that BRD4 could be a major regulator of ATAD5-RLC.
The immunoprecipitation of endogenous ATAD5 confirmed the
binding of ATAD5 toBRD4 (Figure 1E). In human cells, BRD4 is ex-
pressed as three isoforms, BRD4A, BRD4B, and BRD4C (Fig-
ure 1F).All three isoformscontainBD1andBD2andanETdomain.
BRD4A contains a long C-terminal domain that is crucial for its
functionasa transcriptional regulator.BRD4B lacks theC-terminal
domain of BRD4A but contains a unique 78-amino acid sequence
at its C terminus. BRD4B is known to regulate chromatin compac-
tion (Floyd et al., 2013). BRD4C is the shortest isoform.We exam-
ined the interactions between V5-tagged BRD4 isoforms and
FLAG-ATAD5 after transient coexpression (Figure 1F). All three
BRD4 isoforms robustly bound to ATAD5. Because BRD4A is
the most abundant isoform in human cells (Figure S1D), BRD4A
may beamajor interacting partner of ATAD5amongBETproteins.
To identify the ATAD5-binding motif in BRD4, we prepared a
series of BRD4 deletion mutants and examined their interactions
with ATAD5 (Figures 1G and 1H). Immunoprecipitation with
C-terminal deletion mutants of BRD4 revealed that the BRD4
ET domain was crucial for ATAD5 binding (Figure 1G). An ET
domain-null BRD4 fragment, BRD4 (1–597), failed to interact
with ATAD5. Next, we tested whether the region upstream of
the BRD4 ET domain is essential for ATAD5 binding (Figure 1H).Figure 2. ATAD5 Interacts with BRD4 through a Conserved BET Protei
(A) ATAD5 (400–692) binds to BRD4. Top panel: ATAD5 mutants examined for B
ATAD5 (1–32), was fused to the N-terminal-deletion mutants of ATAD5. Bottom pa
was examined by FLAG-immunoprecipitation.
(B) ATAD5 (400–692) is crucial for BRD4 binding. Interactions between endogen
precipitation.
(C) ATAD5 (600–692) is a BET protein-binding domain, BET BD. Interactions be
analyzed by immunoblotting.
(D) Conserved residues in the BET BD are essential for ATAD5 interaction.Mutation
interaction. Top panel: the ATAD5BETBD is well conserved among species. Posit
above the sequence alignment. Center panel: sequences around R656MK658 of A
integrase. Bottom panel: binding of endogenous BRD4A towild-type ormutant FL
the BRD4-ATAD5 interaction.
(E) Full-length FLAG-ATAD5 (BET M2) failed to interact with endogenous BRD4A
(F) E653 and D655 of the BRD4 ET domain are crucial for the interaction with ATAD
(1–719) was analyzed by FLAG-immunoprecipitation. BRD4 (E653R, D655K) and
was not affected by those mutations.
(G) Full-length BRD4A (E653A, D655A) failed to interact with endogenous ATAD5
(H) CUPID analysis was performed to examine the interaction between BRD4B and
cotransfected into 293T cells. After PMA treatment, nuclear membrane localizat
(1–692) comigrated with BRD4B to the nuclear membrane, but the BET M2 muta
(I) Quantification of data in (H).
(J) BRD4 directly interacts with ATAD5. Purified MBP-BRD4B (444–794)-S was m
StrepII affinity purification was performed, and the isolated proteins were analyzed
be copurified with wild-type ATAD5 (500–800). Mutation BET M2 in ATAD5 abro
See also Figure S2.
4636 Cell Reports 29, 4632–4645, December 24, 2019Given that BRD4 (286–297) functions as a nuclear localization
signal (NLS), we fused this NLS sequence to theN-terminal-dele-
tion mutants of BRD4. Immunoprecipitation results showed that
the ET domain alone could bind to ATAD5. These results sug-
gested that BRD4 interacts with ATAD5 through its ET domain.
ATAD5 showed different binding affinities for different BET pro-
teins (Figure 1D), although the sequences of ET domains are
very similar among BRD2, BRD3, and BRD4 (Figure S1E). Re-
gions upstream of the ET domain may have enhanced the inter-
action between BRD4 and ATAD5 (Figure 1H). BRD4 fragments
that contain a region upstream of the ET domain more robustly
bound to ATAD5 as compared to the ET domain alone.
Next, we determined whether DNA damage signaling affects
the BRD4-ATAD5 interaction (Figure S1F). ATAD5 was immuno-
precipitated from cells to which 50 J/m2 UV (harvested after 6 h),
2 mM hydroxyurea (6 h), or 0.02% of methyl methane sulfonate
(MMS, 2 h) was applied. Amounts of coprecipitated BRD4
were not significantly different among the treatments with the
DNA-damaging agents. Therefore, the BRD4-ATAD5 interaction
was not regulated by the DNA damage response.
ATAD5 (596–692) is an ET Domain-Binding Motif
Mutations in the BRD4 ET domain could affect various cellular
processes because BRD4 interacts with several key regulatory
proteins through its ET domain. Therefore, we tried to identify
ATAD5 mutations that specifically disrupt the binding to BRD4
to understand the biological function of the BRD4-ATAD5 inter-
action. We prepared several deletion mutants of ATAD5 and
examined their interaction with endogenous BRD4A (Figure 2A).
ATAD5 (400–692) robustly bound to BRD4A, but ATAD5 (1–400)
did not. This finding was supported by AP-MS data (Figure S2A).
The BRD4A polypeptide (250 kDa) was robustly enriched with
FLAG-ATAD5 (400–692). An ATAD5 fragment that lacks a poly-
peptide between the 400th and the 692nd amino acid residuesn-Binding Domain
RD4 binding. Numbers indicate the positions of deletion. The NLS of ATAD5,
nel: the interaction between endogenous BRD4A and FLAG-ATAD5 fragments
ous BRD4A and FLAG-ATAD5 (D400-692) were examined by FLAG-immuno-
tween endogenous BRD4A and the indicated FLAG-ATAD5 fragments were
s in the predicted b-stranded structure of BETBD abrogated the BRD4-ATAD5
ions of BETM1 (E643LI645 to AAA) and BETM2 (R656MK658 to AAA) are indicated
TAD5 are similar to the BRD4-binding motif of NSD3, CHD4, and of the MLV
AG-ATAD5 (500–692) was analyzed.Mutations BETM1 and BETM2 abrogated
.
5. Binding of ATAD5 (1–692)-FLAG-mNeongreen to wild-type or mutant BRD4
BRD4 (E653A, D655A) failed to interact with ATAD5. ATAD5 binding to UAF1
.
ATAD5 (1–692). PKC-d-mRFC-BRD4B andmNeongreen-ATAD5 (1–692) were
ion of each protein was analyzed by confocal microscopy. Wild-type ATAD5
nt did not. White bars indicate the cross-section used for quantification.
ixed with either wild-type or BET M2 FLAG-ATAD5 (500–800)-StrepII-HALO.
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did not bind to BRD4A (Figure 2B). These results indicated that
the middle region of ATAD5 (i.e., ATAD5 (400–692)) contains a
BRD4-binding motif. This region is located between the UAF1-
binding motif and the PCNA-unloading domain of ATAD5.
To further narrow down the candidate BRD4-bindingmotif, we
dissected ATAD5 (400–692) (Figures 2C and S2B). ATAD5 (400–
600) failed to interact with BRD4A (Figure 2C), but ATAD5 (596–
692) robustly bound to BRD4A (Figure S2B). Based on those
results, we defined ATAD5 (596–692) as a BET protein-binding
domain (BET BD). The BET BD was predicted to form a
b-stranded structure by a secondary-structure prediction pro-
gram (Raptor X; Figure S2C). A b-stranded structure-forming re-
gion is well conserved among various species (Figure 2D). We
mutated two conserved 3-amino acid patches in BET BD to
alanine residues (top panel of Figure 2D). Those residues were
predicted to be within b strands (Figure S2C). The mutations
were designated as BET M1 (E643LI645 to AAA) and BET M2
(R656MK658 to AAA), respectively. BET M1, BET M2, and the
combination of the two mutations, BET M12, abrogated the
interaction between ATAD5 (500–692) and endogenous BRD4A
(bottom panel of Figure 2D). Mutation BET M2 in full-length
ATAD5 also disrupted the interaction with BRD4A (Figure 2E).
Of note, polypeptide sequences around R656MK658 of ATAD5
are similar to BRD4-binding motifs of the MLV integrase,
NSD3, and CHD4 (center panel of Figure 2D) (Crowe et al.,
2016; Zhang et al., 2016). BRD4-binding motifs contain I/L-R/
K-f-R/K-f (f: any hydrophobic amino acid). Furthermore, it
was reported that the BRD4-binding motif of the MLV integrase
and NSD3 forms a b-stranded structure. Some studies showed
that two negatively charged amino acid residues in the BRD4
ET domain, E653 and D655, are crucial for the binding to the
MLV integrase (Crowe et al., 2016). We mutated these two resi-
dues and examined whether thesemutations affect ATAD5 bind-
ing (Figure 2F). Mutation of E653 and D655 to alanine (hereafter
referred to as EDAA) or positively charged amino acids (hereafter
referred to as EDRK) significantly reduced the interaction be-
tween BRD4 (1–719) and ATAD5 (1–692). Full-length BRD4
(EDAA) also failed to interact with endogenous ATAD5 (Fig-
ure 2G). These results suggested that ATAD5, NSD3, CHD4,
and the MLV integrase bind to the BRD4 ET domain in a similarFigure 3. Mitotic Phosphorylation of the ATAD5 BET BD Interferes wit
(A) The N-terminal domain of ATAD5 is phosphorylated in nocodazole-treated
asynchronous or nocodazole-treated cells. Isolated proteins were analyzed by im
during SDS-PAGE. l-phosphatase treatment abrogated the mobility shift.
(B) ATAD5 (1–692) was phosphorylated during mitosis. Cells stably expressing F
released. Cells were harvested at the indicated time points, and the mobility of AT
gradually dephosphorylated after the release from the nocodazole arrest.
(C) Nocodazole treatment attenuated the BRD4-ATAD5 interaction. Cells stably e
was FLAG immunoprecipitated, and coisolation of endogenous BRD4A was exa
(D) The interaction between endogenous ATAD5 and BRD4A is weaker during mito
and coprecipitation of endogenous BRD4A was analyzed by immunoblotting.
(E) S653 of ATAD5 is a mitotic phosphorylation site. Mutation S653A reduced the
more information.
(F) S653 of endogenous ATAD5 is phosphorylated during mitosis. Endogenous A
treatment. S653 phosphorylation of ATAD5 was examined by anti-phospho-S65
(G) Mitotic phosphorylation of ATAD5 S653 interferes with BRD4 binding. Wild-typ
expressed, and their binding to endogenous BRD4A was examined by FLAG im
BRD4 interaction.
See also Figure S3.
4638 Cell Reports 29, 4632–4645, December 24, 2019manner. Reduced ATAD5 binding caused by the EDRKmutation
in the BRD4 ET domain was not restored by a charge conversion
mutation in the ATAD5 BET BD (ATAD5 (R656E K658D);
Figure S2D). This finding suggested that the BRD4-ATAD5 inter-
action does not represent simple electrostatic interactions be-
tween charged amino acids.
To examine the intracellular interaction between ATAD5 and
BRD4, we used cell-based unidentified protein interaction dis-
covery (CUPID) analysis (Lee et al., 2011). The CUPID analysis
has been used for real-time monitoring of protein–protein inter-
actions. In CUPID, a bait protein is fused to protein kinase C-d
(PKC-d) that migrates to the cell membrane during treatment
with phorbol 12-myristate 13-acetate (PMA). A bait-binding pro-
tein comigrated with the bait-PKC-d fusion to the cell membrane.
We performedCUPID analysis withmNeongreen-ATAD5 (1–692)
and PKC-d-mRFP-BRD4B (Figures 2H and 2I). Both proteins
dispersed throughout the nucleus before PMA treatment.
Upon PMA treatment, ATAD5 (1–692) comigrated with PKC-d-
BRD4B to the nuclear membrane. By contrast, BET M2 ATAD5
(1–692) did not comigrate with PKC-d-BRD4B.
To determine whether BRD4 directly interacts with ATAD5, we
conducted an in vitro pull-down experiment with purified pro-
teins (Figure 2J). We purified the BET BD-containing region of
ATAD5, ATAD5 (500–800), and an ET domain-containing C-ter-
minal portion of BRD4B (i.e., BRD4B (444–794)]), in a bacterial
expression system. To increase stability and solubility, an MBP
and a HALO tag were fused to BRD4B (444–794) and ATAD5
(500–800), respectively. Purified proteins were mixed, and then
StrepII-tagged ATAD5 (500–800) was isolated using StrepTactin
Sepharose beads. BRD4B (444–794) was found to be coisolated
with ATAD5 (500–800). Nonetheless, mutation BET M2 in the
BET BD of ATAD5 abrogated the coisolation. These data clearly
showed that the BET BD of ATAD5 directly binds to the ET
domain of BRD4.
Mitotic Phosphorylation Regulates the BRD4-ATAD5
Interaction
We found that ATAD5 (1–692) from nocodazole-arrested cells
migrated more slowly in SDS-PAGE compared to that from G1,
S, or G2 phase cells (Figures 3A and S3A). This mitotic shift ofh BRD4 Interaction
cells. Transiently expressed FLAG-ATAD5 (1–692) was FLAG purified from
munoblotting. Nocodazole treatment induced a mobility shift of ATAD5 (1–692)
LAG-ATAD5 (1–692) were arrested at prometaphase by nocodazole and then
AD5 (1–692) was analyzed by immunoblotting. ATAD5 (1–692) was found to be
xpressing FLAG-ATAD5 (1–692) were treated with nocodazole. ATAD5 (1–692)
mined by immunoblotting.
sis. Endogenous ATAD5 was immunoprecipitated after nocodazole treatment,
mobility shift in the Phos-Tag gel after nocodazole treatment. See Figure S3 for
TAD5 was immunoprecipitated from asynchronous cells or after nocodazole
3 antibody.
e, or the S653A, or the S653D mutant of FLAG-ATAD5 (1–692) was transiently
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Figure 4. Acetyl-Histone-Bound BRD4 Inhibits PCNA Unloading
(A) ATAD5 (500–692) interacts with H4K5Ac and H4K12Ac in a BRD4-dependent manner. FLAG immunoprecipitation was performed on cells expressing the
indicated FLAG-ATAD5 fragments. Coprecipitated endogenous BRD4A and acetyl-histones were analyzed by immunoblotting. Only BRD4-binding ATAD5
fragments copurified with H4K5Ac and H4K12Ac. See Figure S4 for more information).
(B) BRD4 inhibitor JQ1 interferes with the association of acetyl-histones with ATAD5, without affecting the BRD4-ATAD5 interaction. FLAG immunoprecipitation
was performed on the lysates of cells transiently expressing FLAG-ATAD5 (500–692). Next, 0.5 mM (+) or 5 mM (++) JQ1 was applied for a 1-h incubation before
harvesting.
(C) Inhibition of BRD4-acetyl-histone binding reduces the quantity of nascent chromatin-bound PCNA. JQ1 at 1 mM was added before cell harvesting, and
nascent DNA-associated proteins were examined by iPOND analysis. BRD4 inhibition by JQ1 reduced the levels of BRD4 and PCNA on the nascent DNA. The
nascent DNA association of ATAD5 was not affected by JQ1. A relative PCNA amount on nascent DNA was quantified from the data (n = 3, ****p% 0.0001). The
error bar indicates SD.
(legend continued on next page)
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ATAD5 (1–692) was abrogated by l-phosphatase treatment.
These results suggested that ATAD5 is phosphorylated upon
nocodazole-induced arrest. As cells were released from the no-
codazole-induced arrest, the mobility shift of ATAD5 (1–692)
gradually disappeared (Figure 3B). To validate the mitosis-
specific phosphorylation of ATAD5, cells harboring doxycy-
cline-inducible ATAD5 (1–692) were arrested in the G1 phase
by double-thymidine block and then released (Figure S3B). A
mobility shift of ATAD5 (1–692) was observed when the amount
of phospho-histone H3, a mitotic indicator, increased.
Moreover, ATAD5 (400–692) and ATAD5 (500–692), which
contains the BET BD, turned out to be phosphorylated after
nocodazole treatment (Figure S3C). Accordingly, we tested
whether an interaction between BRD4 and ATAD5 changes dur-
ing mitosis. We found that the interaction between ATAD5
(1–692) and BRD4A was significantly reduced by nocodazole
treatment (Figure 3C). Immunoprecipitation of endogenous
ATAD5 after the nocodazole-induced arrest also showed that
the BRD4-ATAD5 interaction was attenuated by the mitotic ar-
rest (Figure 3D).
To figure out how mitotic phosphorylation of ATAD5 inhibits
the BRD4-ATAD5 interaction, we mapped mitotic phosphoryla-
tion sites in ATAD5 (Figure S3D). FLAG-ATAD5 (1–692) was affin-
ity purified from asynchronous cells or nocodazole-arrested
cells, and phosphorylation sites were identified by MS analysis.
We found several phosphorylation sites specifically present in
ATAD5 (1–692) in the nocodazole treatment group. Among
them, the S653 residue is located in a conserved BET-protein-
binding domain. To confirm the mitotic phosphorylation of
S653, we prepared a phospho-dead mutant, S653A, and exam-
ined its mobility shift in a Phos-Tag gel after nocodazole treat-
ment (Figure 3E). As expected, the S653A mutation reduced
the mobility shift.
Mitotic phosphorylation of S653 was further verified with an
anti-phospho-S653 antibody (Figures 3F, S3E, and S3F). The
specificity of the anti-phospho-S653 antibody was validated by
means of the S653A mutation (Figure S3E). S653A ATAD5
(1–692) from nocodazole-arrested cells was not recognized by
the phospho-specific antibody. The anti-phospho-S653 anti-
body specifically detected endogenous ATAD5 that was isolated
from nocodazole-arrested cells (Figure 3F). S653P654 is a putative
cyclin-dependent kinase (CDK) target site. To determinewhether
mitotic CDK phosphorylates ATAD5, a CDK1 inhibitor (RO3306)
was applied to nocodazole-arrested cells (Figure S3F). CDK1 in-
hibition resulted in a loss of S653 phosphorylation (Figure S3F).
These data meant that the S653 residue in the BET BD of
ATAD5 is phosphorylated by mitotic CDK.
Next, we determined whether S653 phosphorylation affects
the BRD4-ATAD5 interaction. A phospho-mimetic S653D
mutant was prepared, and its interaction with BRD4A was(D) Inhibition of histone acetyltransferase diminishes the PCNA level on the nasce
(AA) treatment. AA treatment resulted in a reduction in the nascent DNA-associa
quantified from the data (n = 3, ***p % 0.001). The error bar indicates SD.
(E) Mutation BET M2 did not significantly affect the nascent DNA association of A
either wild-type or BETM2 FLAG-ATAD5 (1–692). Endogenous ATAD5was deplet
an EdU pulse-chase procedure. Nascent DNA association of the indicated prote
See also Figure S4.
4640 Cell Reports 29, 4632–4645, December 24, 2019examined (Figure 3G). S653D mutation significantly decreased
the interaction between ATAD5 and BRD4A. This result sug-
gested that the BRD4-ATAD5 interaction is inhibited during
mitosis. BET proteins may regulate ATAD5 function during
interphase.
ATAD5, BRD4, and Acetyl-Histones Cooperate for
Proper PCNA Unloading
BET proteins bind to acetyl-histones such as H4K5Ac and
H4K12Ac through its BD. These histone marks are enriched in
nascent chromatin (Figure 1B). Therefore, it is possible that
BRD4, ATAD5, and acetyl-histones work together to properly
unload PCNA from nascent chromatin. To test this possibility,
we examined the interactions among BRD4A, ATAD5,
and acetyl-histones (Figures 4A, 4B, and S4A). FLAG-tagged
ATAD5 fragments were FLAG purified after transient expression
(Figures 4A and S4A). The acetylation status of copurified his-
tones was examined with antibodies that are specific for distinct
acetylation marks on histone H3 or H4. We found that H4K5Ac,
H4K12Ac, and H3K9Ac were enriched with ATAD5 (400–692)
and ATAD5 (500–692). Enrichment of acetyl-histones was not
observed with ATAD5 fragments that do not contain the BET
BD. Mutation BET M2 also abrogated the coisolation of acetyl-
histones. JQ1 is an inhibitor for BET proteins that interferes
with the interaction between BRD4 and acetyl-histones (Filippa-
kopoulos et al., 2010). Treatment with JQ1 significantly reduced
the coisolation of H4K5Ac with FLAG-ATAD5 (500–692) without
affecting the interaction between endogenous BRD4A and
ATAD5 (500–692) (Figure 4B). These results suggested that
ATAD5 interacts with acetyl-histone-bound BRD4A.
Next, we examined whether BRD4 regulates PCNA unloading.
After JQ1 treatment, amounts of nascent DNA–bound ATAD5,
BRD4A, and PCNA were monitored by iPOND analysis (Fig-
ure 4C). As expected, the amount of nascent DNA-bound
BRD4A was diminished by the application of JQ1. Of note,
JQ1 treatment reduced the PCNA quantity on nascent DNA.
We inhibited histone acetyltransferase by anacardic acid (AA)
(Figure 4D). AA decreased the amount of H4K5Ac on nascent
chromatin. Downregulation of acetyl-histones by AA treatment
resulted in less BRD4A association with the nascent DNA.
Similar to the JQ1 treatment group, the PCNA level on nascent
DNA diminished after the application of AA. These results sug-
gested that BRD4A negatively regulates PCNA unloading on
the nascent chromatin.
Because the association patterns of ATAD5 and BRD4 with
nascent DNA were similar (Figure S1A), we examined whether
the BRD4-ATAD5 interaction is important for the recruitment of
ATAD5 to nascent chromatin. We monitored nascent DNA
association with ATAD5 (1–692) BET M2 (Figure 4E) or ATAD5
(1–600) (Figure S4B). ATAD5 (1–600) lacks the BET BD. ATAD5nt DNA. EdU pulse-chase iPOND analysis was performed after anacardic acid
ted H4K5Ac, BRD4, and PCNA. A relative PCNA amount on nascent DNA was
TAD5 (1–692). iPOND analysis was performed on cells transiently expressing
ed by siRNA transfection. Cells were harvested at the indicated time points after
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associated with nascent DNA regardless of its BRD4-binding
ability. Therefore, an interaction with BRD4 is not necessary for
nascent DNA association of ATAD5.
The BRD4 Fine-Tunes PCNA Unloading by ATAD5-RLC
If BRD4A inhibits PCNA unloading from nascent chromatin, then
BRD4A depletion should reduce the accumulation of PCNA in
chromatin. To examine this possibility, we monitored the PCNA
level on nascent DNA after a knockdown of ATAD5 and
BRD4A. Because ATAD5-RLC is a major PCNA unloader (Kang
et al., 2019), ATAD5 depletion increased the PCNA quantity on
nascent DNA. Furthermore, the ATAD5 knockdown delayed
PCNA dissociation from nascent DNA (compare lanes 9 and 13
with lanes 10 and 14 in Figure 5A). However, depletion of
BRD4A slightly reduced the binding of PCNA to nascent DNA
(compare lane 9 with lane 11 in Figure 5A). A double knockdown
of BRD4A and ATAD5 more clearly showed the inhibitory action
of BRD4 on PCNA unloading (compare lanes 10 and 14 with
lanes 12 and 16 in Figure 5A). Co-depletion of BRD4A and
ATAD5 resulted inmore rapid dissociation of PCNA from nascent
DNA as compared to ATAD5 depletion alone. These results
implied that BRD4A negatively controls PCNA unloading from
nascent DNA.
Next, we examined the effect of BRD4A overexpression on
PCNA unloading (Figure 5B). Transfection of BRD4A significantly
increased the amount of BRD4A both in the whole-cell extract
and in a chromatin fraction. Of note, the overexpression of
BRD4A increased the amount of chromatin-bound PCNA. In
contrast, an ET domain mutant of BRD4A—BRD4A (EDAA)—
did not induce the accumulation of PCNA in chromatin. These re-
sults also support the notion that BRD4 inhibits PCNA unloading
through its interaction with ATAD5.
As previously reported, the add-back of exogenous ATAD5
into ATAD5-depleted cells reduced the chromatin-bound
PCNA amount (Figures 5C and 5D). ATAD5 (E1173K, EK) is an
ATPase motif mutant and is deficient in PCNA unloading (Kang
et al., 2019). Accordingly, the expression of ATAD5 (E1173K) in
ATAD5-depleted cells failed to decrease the chromatin-accumu-
lated PCNA amount. The add-back of ATAD5 (BET M2) more
strongly diminished the chromatin-accumulated PCNA amountFigure 5. BRD4 Fine-Tunes the PCNA-Unloading Activity of ATAD5-RL
(A) BRD4 depletion enhances PCNA unloading by ATAD5-RLC. After depletion of
nascent DNA was quantified by immunoblotting. The amount of nascent DNA-as
indicate the relative amount of PCNA.
(B) BRD4 inhibits PCNA unloading. After transient overexpression of either wild-ty
BRD4A induced the accumulation of PCNA on chromatin, but BRD4A (EDAA) did
*p < 0.05). The error bar indicates SD.
(C) BETM2mutant ATAD5more robustly unloads PCNA as compared to the wild t
endogenous ATAD5-depleted cells. After chromatin fractionation, chromatin-bo
presented as a control. Less PCNA was observed on the chromatin of BET M2 m
(D) A relative PCNA amount on chromatin was quantified from the data in (C) (n =
(E) The influence of BRD4A on PCNA unloading in vitro. A PCNA-unloading assay w
BRD4A (EDAA). PCNA-unloading activity of ATAD5-RLC was not inhibited by BR
(F) Quantification of DNA-bound PCNA from the data in (E) (n = 3). The error bar
(G) BRD4-ATAD5 interaction is important for DNA replication. Cells harboring d
experiment. Endogenous ATAD5was depleted by siRNA transfection, and ATAD5
incorporation was monitored by flow cytometry. Rectangles indicate the regions
(H) Quantification of data in (G) (n = 3, *p < 0.05). The error bar indicates SD.
See also Figure S5.
4642 Cell Reports 29, 4632–4645, December 24, 2019as compared to the wild-type add-back group. This result also
supports the notion that BRD4A binds to ATAD5 and inhibits
the PCNA-unloading activity of ATAD5-RLC.
To test whether the binding of BRD4A directly inhibits
ATAD5-RLC, we performed an in vitro PCNA-unloading assay
(Figures 5E, 5F, and S5B) (Kang et al., 2019). PCNA was
loaded onto bead-coupled substrate DNA using purified RFC.
Substrate DNA was a 130-mer that contained a 10-nt gap. The
free end of DNA was blocked by transcription activator-like
effector (TALE)-protein binding to prevent a slide-off of DNA-
loaded PCNA. ATAD5-RLC unloaded PCNA, as reported previ-
ously (Figures 5E and 5F). We purified wild-type BRD4A and
BRD4A (EDAA) (Figure S5B) to examine their effect on PCNA un-
loading. BRD4 did not inhibit PCNA unloading in vitro (Figures 5E
and 5F). These data suggested that the inhibition of PCNA un-
loading by BRD4 may require acetyl-histone association with
BRD4-ATAD5.
Next, we determined whether the ATAD5-BRD4 interaction af-
fects DNA replication. We prepared HeLa cell lines that harbor
doxycycline-inducible wild-type or BET M2 ATAD5 (DN400).
ATAD5 (DN400) contains both the BET BD and PCNA-unloading
domain (Kang et al., 2019). Endogenous ATAD5 was depleted by
small interfering RNA (siRNA) transfection, and doxycycline was
applied to turn on ATAD5 (DN400). DNA replication of each
sample was monitored by a 5-ethynyl-20-deoxyuridine (EdU)
incorporation assay (Figures 5G, 5H, and S5C). As reported else-
where, ATAD5 depletion reduced EdU incorporation. Wild-type
ATAD5 (DN400) partially reversed the decrease in EdU incorpo-
ration, but the BET M2 mutant did so less efficiently. These re-
sults suggested that BRD4-mediated fine-tuning of PCNA
unloading facilitates DNA replication.
DISCUSSION
Chromatin status influences DNA replication initiation. The BAH
domain of origin recognition complex 1 (ORC1) facilitates chro-
matin binding of the ORC (Kuo et al., 2012). BRD4 recruits TICRR
to euchromatin and facilitates origin firing (Sansam et al., 2018).
In addition, a chromatin landscape influences multiple steps of
replication initiation in vitro (Azmi et al., 2017). Here, weC
ATAD5 and/or BRD4A, EdU pulse-chase iPOND was performed. PCNA on the
sociated PCNA decreased after BRD4 depletion. Numbers below PCNA blots
pe BRD4A or BRD4A (EDAA), chromatin-bound PCNAwas analyzed. Wild-type
not. A relative PCNA amount on chromatin was quantified from the data (n = 3,
ype.Wild-type, BETM2, or E1173Kmutant ATAD5was transiently expressed in
und PCNA was analyzed by immunoblotting. Blots of a whole-cell extract are
utant-expressing cells compared to the wild-type group.
3, **p % 0.01). The error bar indicates SD.
as performedwith ATAD5-RLC in the presence of purified wild-type BRD4A or
D4A in vitro.
indicates SD.
oxycycline-inducible wild-type or BET M2 ATAD5 (DN400) were used in this
(DN400) was turned on by doxycycline. Cells were EdU pulse labeled, and EdU
for quantification.
demonstrated that chromatin also affects the later stage of DNA
replication: PCNA unloading.
PCNA is especially crucial for discontinuous lagging-strand
synthesis. Therefore, PCNA must be continuously loaded onto
the lagging-strand template. In contrast, PCNA that is accumu-
lated on the nascent DNA must be unloaded. Considering the
amount of Okazaki fragments that are synthesized during S
phase, recycling of PCNA is required to support efficient genome
duplication. PCNA unloading is also important for the completion
of chromosome replication. PCNA molecules that stay between
nucleosomes could interfere with nascent chromatin organiza-
tion. Therefore, PCNA unloading must be finely regulated
because PCNA is crucial both for Okazaki fragment maturation
and for nucleosome deposition. Previously, we showed that
replication proteins can inhibit ATAD5-RLC in vitro to prevent
premature PCNA unloading before Okazaki fragment maturation
(Kang et al., 2019). The present study revealed another regulato-
ry mechanism for PCNA unloading. Acetyl-histone-bound BRD4
negatively regulates ATAD5-dependent PCNA unloading (Fig-
ures 4 and 5). BRD4 may function as a safety break that keeps
ATAD5-RLC inactive until PCNA accomplishes its task on
nascent DNA. The BRD4-binding domain, BET BD, is located
immediately upstream of the PCNA-unloading domain of
ATAD5. To open and unload a PCNA ring, the pentameric
surface of ATAD5-RLC binds to the front face of a PCNA
homotrimer. The interaction between acetyl-histone-bound
BRD4 and ATAD5 may interfere with the access of ATAD5-
RLC to PCNA.
The ATAD5 BET BD bound to the ET domain of BRD4 (Figures
2 and 3). In addition to ATAD5, BRD4 interacts with many pro-
teins through the ET domain. Our results indicate that the BET
BD of ATAD5 is similar to that of known ET-binding proteins.
Therefore, ATAD5 and other ET-binding proteins cannot bind
to a BRD4 molecule at the same time. The BRD4-ATAD5-RLC
complex may function as a discrete unit that regulates timely
PCNA unloading. The interaction between BRD4 and ATAD5
was weakened by mitotic phosphorylation of the ATAD5 BET
BD. Without BRD4 binding, ATAD5-RLC could efficiently unload
PCNA from a mitotic chromosome. Otherwise, separation of
BRD4 and ATAD5 may be required for the mitotic function of
each protein.
Newly synthesized histones, which are deposited on nascent
DNA, undergo acetylation at lysines 5 and 12 (histone H4) in
mammalian cells. It has been suggested that these acetylated
sites facilitate nucleosome deposition on nascent DNA. Because
H4K5Ac and H4K12Ac amounts decrease as a replication fork
progresses (Figure 1B), these acetylated sites specifically mark
the nascent chromatin. On the nascent DNA, PCNA unloading
must be coordinated with chromatin organization. H4K5Ac and
H4K12Ac may be docking sites for chromatin-binding proteins
that bridge PCNA unloading and chromatin status. We propose
that the BRD4-ATAD5 complex engages in cross-talk with the
acetyl-histonemarks on nascent DNA to fine-tune PCNA unload-
ing (Figure S5D). BRD4 was localized to nascent DNA through
binding to acetyl-histones (Figures 4C and S1A). ATAD5 also
migrated to nascent DNA (Figures 1 and 4). It remains to be eluci-
dated how ATAD5 is recruited to the sites of DNA synthesis.
BRD4 binding seems to be unnecessary for the recruitment ofATAD5 to nascent DNA. Once there, BRD4 binds to ATAD5-
RLC and inhibits PCNA unloading (Figures 4 and 5). As a replica-
tion fork proceeds, H4K5Ac and H4K12Ac are deacetylated, and
BRD4 is released from the nascent chromatin. The BRD4 release
can activate ATAD5-RLC for PCNA unloading. As we reported
previously, ATAD5-RLC is released from DNA with PCNA during
unloading (Kang et al., 2019). During the inhibition of ATAD5-
RLC, PCNA remains on nascent DNA and aids in the early steps
of nascent chromatin assembly. Our study provides intriguing
insight into how epigenetic information affects the activity of
replication machinery on nascent DNA.
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ñoz, J., and Fernandez-Capetillo, O. (2013). A proteomic characterization of
factors enriched at nascent DNA molecules. Cell Rep. 3, 1105–1116.
Loyola, A., Bonaldi, T., Roche, D., Imhof, A., and Almouzni, G. (2006). PTMs on
H3 variants before chromatin assembly potentiate their final epigenetic state.
Mol. Cell 24, 309–316.
Maruyama, T., Farina, A., Dey, A., Cheong, J., Bermudez, V.P., Tamura, T.,
Sciortino, S., Shuman, J., Hurwitz, J., and Ozato, K. (2002). A mammalian bro-
modomain protein, brd4, interacts with replication factor C and inhibits pro-
gression to S phase. Mol. Cell. Biol. 22, 6509–6520.
Moldovan, G.L., Pfander, B., and Jentsch, S. (2007). PCNA, the maestro of the
replication fork. Cell 129, 665–679.
Petryk, N., Dalby, M., Wenger, A., Stromme, C.B., Strandsby, A., Andersson,
R., and Groth, A. (2018). MCM2 promotes symmetric inheritance of modified
histones during DNA replication. Science 361, 1389–1392.
Poot, R.A., Bozhenok, L., van den Berg, D.L., Steffensen, S., Ferreira, F., Gri-
maldi, M., Gilbert, N., Ferreira, J., and Varga-Weisz, P.D. (2004). The Williams
syndrome transcription factor interacts with PCNA to target chromatin remod-
elling by ISWI to replication foci. Nat. Cell Biol. 6, 1236–1244.
Reveron-Gomez, N., Gonzalez-Aguilera, C., Stewart-Morgan, K.R., Petryk, N.,
Flury, V., Graziano, S., Johansen, J.V., Jakobsen, J.S., Alabert, C., and Groth,
A. (2018). Accurate Recycling of Parental Histones Reproduces the Histone
Modification Landscape during DNA Replication. Mol. Cell 72, 239–249e.5.
Sabari, B.R., Dall’Agnese, A., Boija, A., Klein, I.A., Coffey, E.L., Shrinivas, K.,
Abraham, B.J., Hannett, N.M., Zamudio, A.V., Manteiga, J.C., et al. (2018). Co-
activator condensation at super-enhancers links phase separation and gene
control. Science 361, eaar3958.
Sansam, C.G., Pietrzak, K., Majchrzycka, B., Kerlin, M.A., Chen, J., Rankin, S.,
and Sansam, C.L. (2018). A mechanism for epigenetic control of DNA replica-
tion. Genes Dev. 32, 224–229.
Shen, C., Ipsaro, J.J., Shi, J., Milazzo, J.P., Wang, E., Roe, J.S., Suzuki, Y.,
Pappin, D.J., Joshua-Tor, L., and Vakoc, C.R. (2015). NSD3-Short Is an
Adaptor Protein that Couples BRD4 to the CHD8 Chromatin Remodeler.
Mol. Cell 60, 847–859.
Shibahara, K., and Stillman, B. (1999). Replication-dependent marking of DNA
by PCNA facilitates CAF-1-coupled inheritance of chromatin. Cell 96,
575–585.
Sirbu, B.M., Couch, F.B., Feigerle, J.T., Bhaskara, S., Hiebert, S.W., and Cor-
tez, D. (2011). Analysis of protein dynamics at active, stalled, and collapsed
replication forks. Genes Dev. 25, 1320–1327.
Sobel, R.E., Cook, R.G., Perry, C.A., Annunziato, A.T., and Allis, C.D. (1995).
Conservation of deposition-related acetylation sites in newly synthesized his-
tones H3 and H4. Proc. Natl. Acad. Sci. USA 92, 1237–1241.
Sun, C., Yin, J., Fang, Y., Chen, J., Jeong, K.J., Chen, X., Vellano, C.P., Ju, Z.,
Zhao, W., Zhang, D., et al. (2018). BRD4 Inhibition Is Synthetic Lethal with
PARP Inhibitors through the Induction of Homologous Recombination Defi-
ciency. Cancer Cell 33, 401–416.e8.
White, M.E., Fenger, J.M., and Carson, W.E., 3rd. (2019). Emerging roles of
and therapeutic strategies targeting BRD4 in cancer. Cell. Immunol. 337,
48–53.
Yang, Z., Yik, J.H., Chen, R., He, N., Jang, M.K., Ozato, K., and Zhou, Q.
(2005). Recruitment of P-TEFb for stimulation of transcriptional elongation
by the bromodomain protein Brd4. Mol. Cell 19, 535–545.
Yu, C., Gan, H., Serra-Cardona, A., Zhang, L., Gan, S., Sharma, S., Johansson,
E., Chabes, A., Xu, R.M., and Zhang, Z. (2018). A mechanism for preventingasymmetric histone segregation onto replicating DNA strands. Science 361,
1386–1389.
Zhang, Z., Shibahara, K., and Stillman, B. (2000). PCNA connects DNA replica-
tion to epigenetic inheritance in yeast. Nature 408, 221–225.
Zhang, Q., Zeng, L., Shen, C., Ju, Y., Konuma, T., Zhao, C., Vakoc, C.R.,
and Zhou, M.M. (2016). Structural Mechanism of Transcriptional Regu-
lator NSD3 Recognition by the ET Domain of BRD4. Structure 24,
1201–1208.Cell Reports 29, 4632–4645, December 24, 2019 4645
STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Mouse monoclonal anti FLAG M2 Sigma-Aldrich Cat#F3165; RRID: AB_259529
Mouse monoclonal anti PCNA Santa Cruz Biotechnology Cat#sc-56; RRID: AB_628110
Acetyl Histone H3 antibody sampler kit Cell Signaling Technology Cat#9927
Acetyl Histone H4 antibody set Merck-Millipore Cat#17-211
Rabbit polyclonal anti Histone H3, CT, pan Merck-Millipore Cat#07-690; RRID: AB_417398
Rabbit polyclonal anti BRD2 Bethyl Cat#A302-583A; RRID: AB_2034829
Rabbit polyclonal anti BRD3 Bethyl Cat#A302-368A; RRID: AB_1907251
Rabbit polyclonal anti BRD4 Bethyl Cat#A301-985A; RRID: AB_1576498
Rabbit polyclonal anti pan BRD4 Sigma-Aldrich Cat#AV39076; RRID: AB_1845434
Rabbit polyclonal anti V5 Sigma-Aldrich Cat#V8137; RRID: AB_261889
Mouse monoclonal anti WDR48 (UAF1) Santa Cruz Biotechnology Cat#sc-514473
Mouse monoclonal anti S tag Sigma-Aldrich Cat#SAB2702227
Mouse monoclonal anti phospho Histone H3 (Ser10) Cell Signaling Technology Cat#9706; RRID: AB_331748
Rabbit polyclonal anti Beta Tubulin Abcam Cat#ab15568; RRID: AB_2210952
Rabbit polyclonal anti Lamin B1 Abcam Cat#ab16048; RRID: AB_10107828
Mouse monoclonal anti Histone H2A.X, phospho (Ser139) Merck-Millipore Cat#05-636; RRID: AB_309864
Rabbit anti human ATAD5 Lee et al., 2010 N/A
Rabbit anti human ATAD5, phospho (Ser653) This paper N/A
Chemicals, Peptides, and Recombinant Proteins




Phorbol 12-myristate 13-acetate (PMA) Sigma-Aldrich Cat#P8139
Hydroxyurea (HU) Sigma-Aldrich Cat#H8627
Methyl methane sulfonate (MMS) Sigma-Aldrich Cat#129925
Nocodazole Sigma-Aldrich Cat#M1404
Lambda protein phosphatase (Lambda PP) New England Biolabs Cat#P0753
Phos-tagTM acrylamide NARD Institute, LTD. Cat#AAL-107
Cdk1 inhibitor (RO-3306) Sigma-Aldrich Cat#SML0569
JQ1 Sigma-Aldrich Cat#SML0974
Anacardic acid Sigma-Aldrich Cat#A7236
Critical Commercial Assays




ATAD5 (1-692) interactome This paper ProteomeXchange: PXD016309
Experimental Models: Cell Lines
HEK293T ATCC Cat#CRL-11268; RRID: CVCL_1926
HeLa ATCC Cat#CCL-2; RRID: CVCL_0030
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Oligonucleotides
BRD4A siRNA sense Floyd et al., 2013 N/A
50-GGGAGAAAGAGGAGCGUGAUU-30
BRD4A siRNA antisense Floyd et al., 2013 N/A
50-AAUCACGCUCCUCUUUCUCCC-30
BRD4B siRNA sense Floyd et al., 2013 N/A
50- GCACCAGUGGAGACUUCGUUU-30
BRD4B siRNA antisense Floyd et al., 2013 N/A
50- AAACGAAGUCUCCACUGGUGC-30
Pan BRD4 siRNA Invitrogen Cat#1299001
ATAD5 siRNA sense Lee et al., 2010 N/A
50- GUAUAUUUCUCGAUGUACAUU 30
ATAD5 siRNA antisense Lee et al., 2010 N/A
50- UGUACAUCGAGAAAUAUACUU 30
AccuTargetTM Negative Control siRNA Bioneer N/A
Recombinant DNA
GFP-BRD2 plasmid Addgene Addgene Cat#65376
GFP-BRD3 plasmid Addgene Addgene Cat#65377
HA-BRD4 plasmid Addgene Addgene Cat#31351
Software and Algorithms
Raptor X web server (structure prediction) Jinbo Xu group http://raptorx.uchicago.edu/StructPredV2/predict/
ZEN (blue edition) Carl Zeiss https://www.zeiss.com/microscopy/int/products/
microscope-software.html
FlowJo Tree Star https://www.flowjo.com/solutions/flowjo/; RRID:
SCR_008520
GraphPad Prism GraphPad Software https://www.graphpad.com/scientific-software/
prism/; RRID: SCR_000306LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources should be directed to and will be fulfilled by the Lead Contact, Dr. Sukhyun Kang
(kangsh@ibs.re.kr). Plasmids generated in this study are available upon request. No other unique reagents were generated.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell culture and cell lines
Human HEK293T cells (purchased from American Type Culture Collection; Manassas, VA) was cultured in Dulbecco’s modified
Eagle’s medium (Hyclone) supplemented with 10% of fetal bovine serum (Hyclone) and 1% of a penicillin-streptomycin solution
(GIBCO) at 37C and 5% CO2. HeLa-derived cell lines that stably express FLAG-tagged ATAD5 proteins were generated by means
of a Flp-InTM system (Thermo Fisher Scientific). Tetracycline-free serumwas used for themaintenance of the stable cell lines carrying
a doxycycline-inducible construct. To synchronize cells in the G1 phase, double thymidine block was performed. Cells were treated
with 2.5 mM thymidine for 17 h. The cells were washed with PBS, and the culture was continued in the regular medium for 10 h. The
cells were treated again with 2.5 mM thymidine for 17 h and washed with PBS. Arrested cells were released from the G1 phase by
cultivation in the regular growth medium. HEK293T and HeLa cells are female.
METHOD DETAILS
Plasmid and siRNA transfection
HEK293T cells were transiently transfected with various plasmids using the X-tremeGENETM HP DNA Transfection Reagent (Roche).
For a protein knockdown, cells were transfected with various siRNAs via Lipofectamine RNAiMAX (Thermo Fisher Scientific).
Plasmid- or siRNA-transfected cells were harvested 48 h after transfection for further analysis.Cell Reports 29, 4632–4645.e1–e5, December 24, 2019 e2
Plasmids
Wild-type ATAD5 or BRD4 and its mutants were cloned into the p3 3 FLAG-CMV10 expression vector (Sigma-Aldrich), pcDNA5/
FRT/TO (Thermo Fisher Scientific), or pcDNA3.1 (Invitrogen). All constructs were confirmed by sequencing. The plasmids used in
this work are listed in Table S1. Point mutations were introduced by site-directed mutagenesis with the QuikChange Site-Directed
Mutagenesis Kit (Agilent Technologies).
siRNAs
BRD4A siRNAs with sequences 50-GGGAGAAAGAGGAGCGUGAUU-30 (sense) and 50-AAUCACGCUCCUCUUUCUCCC-30 (anti-
sense), BRD4B siRNAs with sequences 50- GCACCAGUGGAGACUUCGUUU-30 (sense) and 50- AAACGAAGUCUCCACUGG
UGC-30 (antisense), and siRNAs specific to the 30 untranslated region (UTR) of ATAD5 mRNA with sequences 50- GUAUAUUUCUC
GAUGUACAUU-30 (sense) and 50- UGUACAUCGAGAAAUAUACUU-30 (antisense) were synthesized by Bioneer (South Korea). Non-
targeting control siRNA (AccuTarget Negative Control siRNA) and Pan-BRD4 siRNAs (siRNA ID: HSS141059) were purchased from
Bioneer (South Korea) and Invitrogen, respectively.
iPOND
iPONDwas performed as described by Sirbu et al. (2011) with slight modifications. Briefly, HEK293T cells were pulsedwith amedium
containing EdU (10 mM, Life Technologies) for 20 min. The EdU-labeled cells were washed once with a medium containing 10 mM
thymidine to remove EdU, then a thymidine chase was performed with a medium containing 10 mM thymidine for 0, 10, 30, 60, or
120min. Cells were cross-linked with 1% formaldehyde for 20min at room temperature, quenchedwith 0.125Mglycine, andwashed
with PBS. For the conjugation of EdUwith biotin azide, cells were permeabilized with 0.25% Triton X-100/ PBS and incubated in click
reaction buffer (10 mM sodium-L-ascorbate, 20 mM biotin azide (Life Technologies), and 2 mM CuSO4) for 30 min at room temper-
ature. After centrifugation, the pellets were washed once with 0.5% BSA/PBS and twice with PBS. The cells were resuspended in
lysis buffer (50 mM Tris-HCl pH 8.0, and 1% of SDS) supplemented with protease inhibitors and were sonicated. The lysates
were cleared and then incubated with streptavidin-agarose beads (Novagen) overnight at 4C. The beads were washed once with
lysis buffer, once with 1 M NaCl, and then twice with lysis buffer. To elute proteins bound to nascent DNA, 23 SDS Laemmli sample
buffer was added to packed beads (1:1; v/v). Samples were incubated at 95C for 30 min, loaded on a gel for SDS-PAGE, and
analyzed by immunoblotting.
Immunoprecipitation and western blot analysis
Whole-cell lysates were extracted with buffer X (100mM Tris-HCl pH 8.5, 250mMNaCl, 1 mM EDTA, 1% of Nonidet P-40, and 5 mM
MgCl2) supplemented with the cOmplete protease inhibitor cocktail (Roche), phosphatase inhibitor PhosSTOP (Roche), and 500 U of
Benzonase for 40 min at 4C. Lysates were cleared by centrifugation (13,0003 g, 4C, and 5 min). Protein concentration was deter-
mined by the Bradford Assay (Bio-Rad). FLAG-tagged ATAD5 proteins were incubated with anti-FLAG M2 agarose affinity beads
(Sigma-Aldrich, A2220), and V5-tagged BRD4 proteins were incubated with anti-V5-agarose-affinity beads (Sigma-Aldrich,
A7345) for 1 h at 4C, with constant rotation. The beads were washed three times with buffer X, and the anti-FLAG-bead–bound pro-
teins were eluted with buffer X containing 0.15 mg/ml FLAG peptide. Anti-V5-bead–bound proteins were resuspended in 2 3 SDS
loading buffer and boiled at 100C for 5 min. Coimmunoprecipitated proteins were loaded onto SDS-PAGE and analyzed by immu-
noblotting. The proteins were detected bymeans of a ChemiDocMP imaging system (Bio-Rad). The signal intensity of the bandswas
quantified by ImageLab software version 5.2.1 (Bio-Rad). To detect a phospho-shift, we ran SDS-PAGE in a 5% gel with Phos-TagTM
Acrylamide AAL-107 (25 mM, NARD Institute) and 50 mM MnCl2.
Antibodies
The following antibodies were used: an anti-FLAG antibody (Sigma-Aldrich, F3165, 1:1000); anti-PCNA (PC10) antibody (Santa Cruz
Biotechnology, sc-56, 1:2000); Acetyl-Histone H3 Antibody Sampler Kit (Cell Signaling Technology, #9927, 1:2000); Acetyl-Histone
H4 Antibody Set (Merck-Millipore, #17-211, 1:2000); anti–histone H3 antibody (Merck-Millipore, #07-690, 1:5000); anti-BRD2 anti-
body (Bethyl, A302-583A, 1:1000); anti-BRD3 antibody (Bethyl, A302-368A, 1:1000); anti-BRD4 antibody (Bethyl, A301-985A,
1:1000); Pan-BRD4 antibody (Sigma-Aldrich, AV39076, 1:1000); anti-V5 antibody (Sigma-Aldrich, V8137, 1;2000); anti-UAF1 anti-
body (Santa Cruz Biotechnology, sc-514473, 1:500); anti-S tag antibody (Sigma-Aldrich, SAB2702227, 1:5000); anti-phospho-
histone H3 (Ser10) antibody (Cell Signaling Technology, #9706, 1:1000); anti-beta-tubulin antibody (Abcam, ab15568, 1:2000);
anti-lamin B1 antibody (Abcam, ab16048, 1:1000); anti-phospho-histone H2A.X (Ser139) (Merck-Millipore, #05-636, 1:2000). The
anti-phospho-S653 ATAD5 antibody (1:1000) and anti-human ATAD5 antibody (1:1000) were raised in rabbits.
AP-MS analysis
For liquid chromatography with tandem mass spectrometry, the gel was destained, and bands were cut out and processed as fol-
lows. Briefly, the protein bands were divided into 10 mm sections and subjected to in-gel digestion with trypsin. The tryptic digests
were separated by online reversed-phase chromatography on a Thermo Scientific Eazy nano LC 1200 UHPLC system equipped with
an autosampler using a reversed-phase peptide trap Acclaim PepMapTM 100 column (75 mm inner diameter, 2 cm length) and a
reversed-phase PepMapTM RSLC C18 analytical column (75 mm inner diameter, 15 cm length, 3 mm particle size), both from Thermoe3 Cell Reports 29, 4632–4645.e1–e5, December 24, 2019
Scientific, followed by electrospray ionization at a flow rate of 300 nl/min. The chromatography system was coupled in line with an
Orbitrap Fusion Lumos mass spectrometer. Spectra were searched against the UniProt-human DB in Proteome Discoverer 2.1 soft-
ware via the Sequest-based search algorithm, and comparative analysis of proteins identified in this study was performed in Scaffold
4 Q+S.
CUPID analysis
Plasmids PKC-d-mRFC-BRD4B and either mNeongreen-ATAD5 (1–692)WT or BETM2were cotransfected into HEK293T cells. After
48 h, the cells were treated with a translocation signal activator (PMA) and then fixed with 3.7% formaldehyde. CUPID images were
captured by means of a laser scanning confocal microscope (LSM 880, Carl Zeiss) with a C-Apochromat 40X/1.2 water immersion
lens (488 nm argon laser/505-550 nm detection range for mNeongreen, 561 nm solid state laser/586-662 nm detection range for
mRFP). The fluorescence intensity at a cross-section of the nuclear membrane was analyzed in the ZEN blue software (Carl Zeiss).
Protein purification
Proteins for in vitro PCNA unloading were purified as described elsewhere (Kang et al., 2019). BRD4A was expressed and purified
using a Bac-to-Bac Baculovirus expression system (Thermo Fisher Scientific). The expression construct for BRD4A contains an
N-terminal 10 3 HIS-tag and a C-terminal 3 3 FLAG tag. Viruses were prepared in Sf9 cells, and proteins were expressed in Hi-5
cells. ATAD5 (500–800) and BRD4B (444–794) were cloned into bacterial expression vectors pET-19b (Merck-Millipore) and
pRSF-1b (Merck-Millipore), respectively, then were expressed in E. coli BL21 (DE3) cells (Enzynomics) and Rosetta 2 (Merck-Milli-
pore). Expression constructs for ATAD5 (500–800) and its BET M2 mutant contain an N-terminal 10 3 HIS-33 FLAG tag and C-ter-
minal StrepII-HALO tag. BRD4B (444–794) was taggedwith anN-terminal 63HIS-33 FLAG-MBP tag andC-terminal S tag. To purify
proteins from E. coli cells, 1 L cultures were grown to OD of 0.4, and protein expression was induced by the addition of 1M isopropyl
b-D-1-thiogalactopyranoside (IPTG) for 4 h incubation. E. coli cells were resuspended in Buffer H (25 mMHEPES pH7.5, 1 mMEDTA,
1 mM EGTA, 2.5 mMmagnesium acetate, 10% of glycerol, 1 mM ATP, and 0.02% of NP40) plus 300 mM KCl, with a complete pro-
tease inhibitor cocktail (Roche) and were lysed with lysozyme. The cell lysates were cleared by ultracentrifugation (36,000 3 g,
60 min). Proteins were purified by sequential application of cOmplete HIS-Tag resin (Roche), anti-FLAG M2 agarose resin (Sigma-
Aldrich), and ion exchange chromatography. Purified proteins were analyzed by SDS-PAGE.
An in vitro pull-down assay
10 pmol of purified wild-type or BET M2 FLAG-ATAD5 (500–800)-StrepII-HALO and 10 pmol of purified MBP-BRD4B (444–794)-S
were mixed in Buffer H plus 100 mM KCl for 1 h at 4C. The mixtures were combined with Streptactin Sepharose beads (GE Health-
care) for 1 h at 4C. Beads were collected and washed three times with Buffer H plus 100 mM KCl. Bead-associated proteins were
eluted with Buffer H plus 100 mM KCl containing 10 mM desthiobiotin, then analyzed by immunoblot or Krypton staining.
Chromatin fractionation
This procedure was performed as described previously (Kang et al., 2019). Cells were lysed with buffer A (100 mM NaCl, 300 mM
sucrose, 3mMMgCl2, 10mMPIPES pH 6.8, 1 mMEGTA, and 0.2% of Triton X-100, containing the phosphatase inhibitor PhosSTOP
(Roche) and cOmplete protease inhibitor cocktail (Roche) for 8min on ice. Crude lysates were centrifuged at 50003 g at 4C for 5min
to separate the chromatin-containing pellet from the soluble fraction. The pellet was digested with 50 U of Benzonase (Enzynomics)
for 40 min in RIPA buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM EDTA, 1% of Triton X-100, 0.1% of SDS, 0.5% of sodium
deoxycholate, 1 mM PMSF, 5 mMMgCl2, containing the phosphatase inhibitor PhosSTOP (Roche) and cOmplete protease inhibitor
cocktail (Roche) to extract chromatin-bound proteins. The chromatin-containing fractions were clarified by centrifugation (13,0003
g, 4C) for 5 min to remove debris. Protein concentration was determined by the Bradford Assay (Bio-Rad), and the proteins were
analyzed by western blotting.
The PCNA-unloading reaction
Initially, 20 mL of 2 3 loading reaction buffer (50 mM HEPES pH 7.5, 24 mM magnesium acetate, 0.2 mM zinc acetate, 2 mM dithio-
threitol, 40 mM phosphocreatine, 12 mMATP, 0.04% of NP40, 20% of glycerol, 0.8 mg/ml bovine serum albumin, and 23 cOmplete
protease inhibitor cocktail (Roche) was mixed with 20 mL of a protein mixture (25 mM HEPES pH 7.5, 300 mM potassium acetate
(KoAc), 1 mM EDTA, 1 mM EGTA, 2.5 mM magnesium acetate, 10% of glycerol, 1 mM dithiothreitol, 1 mM ATP, and 0.02% of
NP40) that contains RFC (12.5 nM) and PCNA (250 nM). The PCNA loading reaction was carried out by the addition of 40 mL of
the reaction mixture to a bead-conjugated DNA substrate. The reaction mixture was incubated in a Thermomixer (Eppendorf) for
30 min at 37C and 1200 rpm. After that, the remaining RFC and unbound PCNA were removed by washing the beads once with
0.3 M KCl, twice with 0.5 M KCl, and once again with 0.3 M KoAc Buffer H. For the PCNA-unloading reaction with BRD4, 20 mL
of 23 loading reaction buffer was mixed with 20 mL of the protein mixture that contained various amounts of ATAD5-RLC, with titra-
tion by means of various amounts of BRD4. The unloading reaction mixture was added to collect DNA-beads on which PCNA was
loaded. The unloading reaction mixture was incubated in a Thermomixer for 15 min at 37C. Next, the reacted beads were washed
with 0.3MKCl Buffer H three times. Finally, DNAwas resuspended in 15 mL of digestion buffer (25mMTris-HCl pH 7.5, 100mMKoAc,Cell Reports 29, 4632–4645.e1–e5, December 24, 2019 e4
5 mM CaCl2, and 5 mM MgCl2) containing 1 U of DNase I (Promega). DNA was digested for 10 min, beads were separated using a
magnet, and the supernatants were collected. PCNA on DNA was quantified by immunoblotting.
An EdU incorporation assay
HeLa cells harboring doxycycline-inducible wild-type or BET M2 ATAD5 (DN400) were labeled with 10 mM EdU for 30 min. For flow
cytometry, samples were prepared using the Click-iTTM Plus EdU Alexa FluorTM 647 Flow Cytometry Assay Kit (Invitrogen) and sub-
jected to flow-cytometric analysis (FACSVerse flow cytometer, BD Biosciences). Data were analyzed in the FlowJo software (Tree
Star).
QUANTIFICATION AND STATISTICAL ANALYSIS
Quantification of immunoblots was performed using Bio-Rad Image Lab. Statistical analyseswere completed usingGraphPad Prism.
Statistical details of individual experiments are described in the figure legends and results section. Unless otherwise stated, all ex-
periments were performed three times and representative experiments were shown. Bar graphs with mean and standard deviation
were presented. Individual data points were overlaid with graphs as scatter dot plot. In all cases, *p < 0.05, **p% 0.01, ***p% 0.001,
and ****p % 0.0001.
DATA AND CODE AVAILABILITY
ATAD5 (1-692) interactome data are available via ProteomeXchange with identifier PXD016309. All original data are available upon
request.e5 Cell Reports 29, 4632–4645.e1–e5, December 24, 2019
